Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENERGIZE-T
2024-512747-23-00Phase 3Authorised
- Sponsor
- Agios Pharmaceuticals
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in alpha thalassemia, beta thalassemia, hemoglobin E beta thalassemia (HbE/β-thal) and 1 more comparing Mitapivat with Placebo (2 arms). Primary endpoint: Transfusion reduction response. Planned start Jul 2024; status: authorised.
02
Drugs
mitapivat
03
Conditions
alpha thalassemiabeta thalassemiahemoglobin E beta thalassemia (HbE/β-thal)alpha-thalassemia intermedia
Beyond the preview
Go deeper on 2024-512747-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512747-23-00.